AAN 2022 | Using the visual pathway to treat MS

Treatments capable of remyelination are a significant unmet need for patients with multiple sclerosis (MS). Christian Cordano, MD, PhD, UCSF Weill Institute for Neurosciences, San Francisco, CA, discusses the visual pathway as a measure to study remyelination. A study on patients with relapsing MS and chronic demyelin­ating optic neuropathy receiving clemastine showed that patients experi­enced a reduction in latency delay on full-field visual-evoked potentials while on the antihistamine treatment, demon­strating that the drug has a possible remyelinating effect and highlighting the value of ophthal­mology in treating MS. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.